Johnson & Johnson announces collaboration with U.S. Department of Health and Human Services to fight influenza

Johnson & JohnsonJohnson & Johnson (NYSE: JNJ) announced that Janssen Research & Development LLC (Janssen) are collaborating with the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) to develop a comprehensive portfolio of therapeutics and vaccines to protect communities in the event of an influenza pandemic and other infectious disease threats.

"Speeding the development of bio-preparedness countermeasures such as new therapies and vaccines requires that the private and public sectors join forces. No single government or company can do it alone," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. "By bringing together the excellent scientific capabilities of Janssen with the world-class expertise of BARDA, this partnership enables us to accelerate our science and work towards having improved treatments for seasonal influenza and effective therapies in place should a pandemic arise."

Today, there are more than one billion cases of influenza globally each year, resulting in approximately five million cases of severe illness and up to half a million deaths.(1) The new collaboration has been formed as the centenary of the world's worst influenza pandemic approaches. In 1918, the "Spanish Flu" caused approximately 50 million deaths worldwide and experts predict that a pandemic could be far more devastating if it happened in today's globally mobile world.(2,3) New innovations for influenza are needed to address the shortcomings of current preventative and therapeutic options as well as concerns about the growing emergence of antiviral resistance.

Through this agreement, created under the U.S. Government's Other Transaction Authority (OTA), Janssen and BARDA, a component of ASPR, will invest equally to advance Janssen's extensive portfolio of investigational influenza medicines and vaccines throughout the duration of the collaboration. This portfolio based partnership and combined investment will ensure that vital research is made possible.

Assets within Janssen’s portfolio include JNJ-5806 (formerly AL-794), a potent small molecule inhibitor of influenza A and B viruses including strains with pandemic potential, and a "universal" vaccine candidate, which aims to protect against all influenza strains. Additional investigational products in the portfolio include therapeutic monoclonal antibodies, as well as new targets for emerging pathogens of potential public health concern.

BARDA began using OTAs to create innovative business partnerships with industry that ensure more products reach the market, and that the public has access to important countermeasures. If new medicines from this portfolio are approved, Janssen will work with relevant health stakeholders to ensure that these products are accessible.

This agreement further builds on the collaborations Janssen and BARDA have already established in influenza with pimodivir, our potential first-in-class inhibitor of the PB2 subunit of the influenza A polymerase complex, as well as in response to the 2014 Ebola outbreak in West Africa. This partnership provides a further portfolio of potential solutions to address the impact of influenza.

About Johnson & Johnson
Caring for the world... one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 132,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

About Janssen
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it.

1. World Health Organization. Influenza (seasonal). [Online]. Available at: http://www.who.int/mediacentre/factsheets/fs211/en/ Last accessed September 2017.
2. Taubenberger, J. et al. 1918 Influenza: The Mother of All Pandemics. Emerg Infect Dis. 2006;12(1):15-22. https://dx.doi.org/10.3201/eid1201.050979
3. The Next Pandemic: On the Front Lines Against Humankind’s Gravest Dangers. Khan A., Patrick W. 9781610395915. Public Affairs, 2016.

Most Popular Now

Chemists characterize the fatal fungus among us

Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenge...

FDA approves first cancer drug through new oncolog…

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopa...

Discovery of kidney cancer driver could lead to ne…

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic...

The immune system: T cells are built for speed

Without T cells, we could not survive. They are a key component of our immune system and have highly sensitive receptors on their surface that can detect pathogens. The e...

FDA approves first targeted treatment for patients…

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (...

Women and older people under-represented in drug t…

Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common ...

Novartis renews drug donation of Egaten® (triclabe…

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) ...

Pfizer initiates pivotal Phase 3 program for inves…

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evalu...

Sanofi and REVOLUTION Medicines launch global part…

Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cell...

Novartis marks a new era for migraine patients wit…

Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days p...

FDA grants Breakthrough Therapy Designation for Ro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) i...

New findings suggest allergic responses may protec…

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial Col...